Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Cash from Investing Activities (2022 - 2025)

TriSalus Life Sciences' Cash from Investing Activities history spans 4 years, with the latest figure at -$41000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 18.0% year-over-year to -$41000.0; the TTM value through Dec 2025 reached -$838000.0, down 142.9%, while the annual FY2025 figure was -$838000.0, 142.9% down from the prior year.
  • Cash from Investing Activities reached -$41000.0 in Q4 2025 per TLSIW's latest filing, up from -$176000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $93000.0 in Q2 2025 to a low of -$1.6 million in Q3 2022.
  • Average Cash from Investing Activities over 4 years is -$284812.5, with a median of -$70000.0 recorded in 2023.
  • The largest YoY upside for Cash from Investing Activities was 255.0% in 2025 against a maximum downside of 981.82% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at -$272000.0 in 2022, then plummeted by 36.76% to -$372000.0 in 2023, then surged by 86.56% to -$50000.0 in 2024, then grew by 18.0% to -$41000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Cash from Investing Activities are -$41000.0 (Q4 2025), -$176000.0 (Q3 2025), and $93000.0 (Q2 2025).